{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.7","upperLimit":"71.1","value":"42.9"},{"groupId":"OG001","lowerLimit":"17.3","upperLimit":"52.8","value":"33.3"},{"groupId":"OG002","lowerLimit":"26.6","upperLimit":"66.6","value":"46.2"},{"groupId":"OG003","lowerLimit":"23.1","upperLimit":"68.5","value":"45.0"},{"groupId":"OG004","lowerLimit":"40.8","upperLimit":"84.6","value":"65.0"},{"groupId":"OG005","lowerLimit":"12.8","upperLimit":"64.9","value":"35.7"},{"groupId":"OG006","lowerLimit":"32.8","upperLimit":"74.4","value":"54.2"},{"groupId":"OG007","lowerLimit":"12.2","upperLimit":"73.8","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"24"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"CRR is defined as stringent complete response (sCR) or complete response (CR), according to IMWG criteria. Participants without any reported disease response assessments will be considered non-responders.\n\nsCR=complete response plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry; CR=negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow aspirates","dispersionType":"95% Confidence Interval","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG005","title":"Phase 1 Anakinra 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG006","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG007","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"NUMBER","populationDescription":"All participants who received conforming JCARH125 cell product at the recommended phase 2 dose (and at least one dose of anakinra as prophylactic intervention for phase 1 Anakinra) and have measurable disease at the last disease assessment prior to receiving JCARH125 infusion","reportingStatus":"POSTED","timeFrame":"From the time of the JCARH125 infusion until disease progression, end of study, or the start of another anticancer therapy or stem cell transplant (Up to aproximately 61 months)","title":"Complete Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Percent of participants"}